• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies
AbstractLipoprotein(a), or Lp(a), is structurally like low-density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined, and it is estimated that 20-25% of the global population has an Lp(a) level ≥50 mg/dL (or ≥125 nmol/L). Diet and lifestyle interventions have little to no effect on Lp(a) levels. Lipoprotein apheresis is the only approved treatment for elevated Lp(a) but i...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 19, 2023 Category: Drugs & Pharmacology Authors: Ibrahim S. Alhomoud, Azita Talasaz, Anurag Mehta, Michael Kelly, Evan M. Sisson, John D. Bucheit, Roy Brown, Dave L. Dixon Tags: REVIEW Source Type: research

Inclisiran: A Novel Small Interfering RNA Drug for LDL Reduction
This article is protected by copyright. All rights reserved.PMID:35279835 | DOI:10.1002/jcph.2045
Source: The Journal of Clinical Pharmacology - March 13, 2022 Category: Drugs & Pharmacology Authors: Kimberly W Smith C Michael White Source Type: research